Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.

Drug Category : Array
Conference Category : Array
Lead Author : Sharman J, et al.
Published Date : 08/11/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/UTX%20IB%20MCL%20ASH%202015%20FINAL.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top